^
Association details:
| Biomarker: | Chr t(14;16) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | Proteasome inhibitor + Immunomodulator |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cytogenetic abnormalities in MM: Association with disease characteristics and treatment response.
Published date:
05/29/2020
Excerpt:
The rate of ≥ very good partial response was higher for patients with high risk IgH translocations [t(4;14), t(14;16) or t(14;20)] compared to standard risk with PI-IMiD combination treatment (88% vs 65% P < 0.01).
DOI:
10.1200/JCO.2020.38.15_suppl.e20520
Source:
Title:
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Published date:
05/22/2020
Excerpt:
CONTRADICTING EVIDENCE: We characterized patients as having documented C1As or other high-risk chromosomal abnormalities (HRCAs) as defined by the Revised-International Staging System (R-ISS) such as del(17p), t(14;16), and t(4;14)….Compared with patients without C1As, patients with C1As were more likely to have higher stage (R-ISS stage III; 18% vs 12%), to have HRCAs (27% vs 14%), and to receive combinations of proteasome inhibitors and immunomodulatory agents (41% vs 34%). Median OS was lower for patients with C1As (46.6 vs 70.1 months; log-rank P < .001). C1As were independently associated with worse OS (adjusted hazard ratio, 1.42; 95% confidence interval, 1.19-2.69; P < .001)...
DOI:
doi.org/10.1182/bloodadvances.2019001425
